The Manufacturers Life Insurance Company Boosts Stock Position in Gossamer Bio, Inc. (NASDAQ:GOSS)

The Manufacturers Life Insurance Company lifted its position in Gossamer Bio, Inc. (NASDAQ:GOSS) by 24.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 385,133 shares of the company’s stock after buying an additional 74,920 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.17% of Gossamer Bio worth $380,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of GOSS. US Bancorp DE purchased a new stake in Gossamer Bio during the 3rd quarter worth about $39,000. Choreo LLC acquired a new position in shares of Gossamer Bio during the 2nd quarter worth about $46,000. GSA Capital Partners LLP acquired a new position in shares of Gossamer Bio during the 3rd quarter worth about $67,000. Algert Global LLC acquired a new position in shares of Gossamer Bio during the 2nd quarter worth about $75,000. Finally, Sequoia Financial Advisors LLC boosted its position in shares of Gossamer Bio by 27.2% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock worth $84,000 after acquiring an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research report on Monday, November 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Gossamer Bio presently has a consensus rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Stock Up 2.2 %

Shares of NASDAQ GOSS opened at $0.93 on Monday. The stock has a market cap of $210.74 million, a PE ratio of -2.91 and a beta of 1.85. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio, Inc. has a 52-week low of $0.50 and a 52-week high of $1.60. The business has a 50-day moving average price of $0.84 and a 200 day moving average price of $0.87.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The firm had revenue of $9.48 million during the quarter, compared to analyst estimates of $4.52 million. Equities research analysts forecast that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.